IL9 and Miyoshi myopathy: All of these are associated with MM progression; high IL-9 levels are related to resistance to proteasome inhibitor therapy, SDF-1α activates MM cells, and an increase in IL-22-producing TH22 cells is associated with a poor prognosis for MM patients [35,36,37].